SCHEMBL5124327

SCHEMBL5124327

COc1ccc(CNc2nc(-c3cnccn3)nc3scc(C)c23)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.44
NOD1 Q9Y239 1/20 0.44
ESR1 P03372 1/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPK1 P28482 1/20 0.41
POLB P06746 2/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
APP P05067 2/20 0.39
TGFBR1 P36897 1/20 0.39
MRGPRX1 Q96LB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5122177 0.92 ESR1 (0.45) ESR1PDE5AADORA2A
SCHEMBL5129883 0.88 KDM4E (0.52) TNFNOD1ESR1MEN1KMT2A
SCHEMBL5119865 0.85 MEN1 (0.52) TNFNOD1ESR1MAPTMEN1
SCHEMBL5128670 0.85 SMN1; SMN2 (0.44) TNFNOD1SMN1; SMN2MEN1KMT2A
SCHEMBL5118580 0.85 ALDH1A1 (0.55) MAPTSMN1; SMN2CYP1A2CYP3A4CYP2D6
SCHEMBL5122486 0.85 ESR1 (0.48) ESR1TGFBR1ADORA2A
SCHEMBL5122443 0.84 ESR1 (0.49) ESR1MAPTKDM4EPOLBTGFBR1
SCHEMBL5123241 0.84 CHRM4 (0.42) TNFNOD1MAPTSMN1; SMN2MEN1
SCHEMBL5118982 0.83 ESR1 (0.47) ESR1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL5122834 0.82 NPC1 (0.48) TNFNOD1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 TNF 2769/4885NOD1 1451/4885ESR1 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.